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This communication provides a report of the Pharma-
ceutical Interest Group Workshop held on Tuesday,
June 10th, 2003, during the 51st ASMS Conference on
Mass Spectrometry and Allied Topics in Montreal,
Canada. The subject of the workshop, cassette dosing
(CD), was selected to address two objectives. The first
objective was to demonstrate the capacity the ASMS
Pharmaceutical Interest Group to serve as a conduit for
benchmark analysis on a topic of pharmaceutical inter-
est. A secondary motive was to use the workshop to
provide a forum for active discussion and debate. CD is
a topic that met both objectives since it is a controversial
subject for which no clear consensus exists within the
pharmaceutical industry regarding it use.
As anticipated, the topic of CD sparked lively dis-
cussion from the nearly 150 society members in atten-
dance. To facilitate bench marking, an informal survey
on CD practices was conducted prior to the meeting.
The results from this survey, which were presented at
the workshop, are the subject of the present communi-
cation.
The beginning of the workshop was devoted to
general business including the dissemination of infor-
mation about the ASMS Pharmaceutical Interest Group.
As this information will not be reviewed here, inquiries
should be directed to the current chair, Brad Acker-
mann (ackermann_bradley_l@lilly.com).
Background on Cassette Dosing
Cassette dosing (a.k.a. N-in-one) refers to the practice of
simultaneously dosing laboratory animals with multi-
ple compounds, typically to accelerate the pace of
exposure screening. This practice, made possible by the
extraordinary specificity of tandem MS detection, is
seen as a way to maximize the utilization of expensive
LC/MS/MS instrumentation and to minimize the num-
ber of animals used. Since the initial reporting of
N-in-one dosing by Berman and co-workers in 1997 [1],
several reports have appeared in the literature [2–5].
Interested readers are also referred to a seminal article
by White and Manitpisitkul on the pharmacokinetic
implications of CD [6].
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tions at the workshop on their experience with CD.
Cornelius Hop (Pfizer, Groton, CT) shared information
related to the consistency of a reference compound
dosed in both I.V. and P.O. routes over the course of 45
experiments. Although the results were fairly consis-
tent, differences as high as 5-fold were observed for
several PK parameters.
Jing-Tao Wu (Millennium Pharmaceuticals, Cam-
bridge, MA) provided an overview of the use of CD in
his laboratory, which included a comparison of single
compound and cassette administration (N  5) for 28
compounds. The half-life values (T 1/2) obtained by the
two methods were compared to see how often results
produced by CD were outside of the variation ex-
plained by single compound administration. Outliers
were identified as values  4  from the mean value
observed from single compound administration. The
outcome of this experiment was that 75% of the com-
pounds studied exhibited no change, 21.4% were con-
sidered false positives, and 3.6 % were classified as false
negatives. Because false positives are not removed from
future screening, the risk of cassette dosing (N 5) was
taken as 3.6%. This risk was deemed acceptable by the
author since a 2.5-fold increase in the rate of exposure
screening was achieved using the practices described.
Questionnaire on Cassette Dosing
Practices
The remainder of the workshop was devoted to the
questionnaire, which consisted of 13 multiple-choice
questions. The primary group targeted was bioanalyti-
cal experts having either direct experience with CD or
an informed opinion on the subject. Several question-
naires were sent both within and outside the United
States yielding a total of 37 responses. Of these, “Large
Pharma”, defined as companies with more than 15,000
employees, accounted for 70 percent of the total re-
sponses representing 12 major pharmaceutical compa-
nies. The percentage of responses from “Small Pharma/
Biotechs” was 16 percent. Contract research
organizations (CROs) accounted for 11 percent of the
total responses. When the respondents were asked
about their work function, 60 percent indicated they
support drug discovery ADME compared with 33 per-
cent who support either preclinical (GLP) or clinical
bioanalysis.
The results of the questionnaire were presented in
sequential order allowing time for group discussion
after each question. The questionnaire is reproduced
below. The responses to each question are listed in
parentheses.r Inc.
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your facility
(a) Never (25%)
(b) Seldom—according to project or
upon request (51%)
(c) Approximately equal to single
compound administration based
on the number of doses (16%)
(d) Default method used for exposure
screening (8%)
QUESTION 2: What is the average number of com-
pounds per cassette?
(a) N  3 to 4 (52%)
(b) N  5 to 7 (41%)
(c) N  8 to 10 (7%)
(d) N  10 (0%)
QUESTION 3: Which species have you employed for
cassette dosing?
(a) Mouse (17%)
(b) Rat (59%)
(c) Dog (17%)
(d) Monkey (7%)
(e) Other (0%)
QUESTION 4: How often are cassettes administered
by a route other than P.O.?
(a) 10% (27%)
(b) 10 to 49% (23%)
(c) 50 to 74% (12%)
(d) 75% (38%)
QUESTION 5: How much do formulation issues in-
fluence cassette dosing?
(a) Very little (51%)
(b) Adds noticeable overhead to
setup time (39%)
(c) P.O. dosing used primarily to
minimize formulation issues
(10%)
(d) Cassette dosing not performed in
part due to formulation issues
(0%)
QUESTION 6: What best describes the reference
compound co-administered with each
cassette for a given SAR?
(a) Current lead (subject to change as
SAR progresses) (15%)
(b) A well-characterized compound
within the SAR (not subject to
change) (39%)
(c) A well-characterized compound
not belonging to the SAR (12%)
(d) A reference compound is not typ-
ically dosed with cassettes (27%)QUESTION 7: What MS controls are used with cas-
sette dosing? [Results are normalized
to response (a)]
(a) Compounds of the same MW are
not co-administered (100%)
(b) Compounds related by likely me-
tabolite shifts are not co-adminis-
tered (64%)
(c) MS/MS cross-talk examined for
co-administered compounds
(77%)
(d) An internal standard is used for
all analysis (82%)
QUESTION 8: Cassette dosing extends analysis time
(i.e., method development, sample
preparation, sample analysis, and
data processing) by what factor?
(a) No difference relative to single
compound administration (19%)
(b) 50 percent more time needed for
cassette dosing (54%)
(c) 100 percent more time needed for
cassette dosing (19%)
(d) 100 percent more time needed
for cassette dosing (8%)
QUESTION 9: Is extra analytical effort applied when
cassette dosing is used?
(a) LC conditions selected to maxi-
mize throughput (run time not
extended) (32%)
(b) Fast LC conditions used, but
cross-talk avoided (run time not
extended) (32%)
(c) Run time extended, although LC
separation not necessary unless
cross-talk observed (25%)
(d) LC resolution ensured for all co-
administered compounds (11%)
QUESTION 10: What is your primary motivation for
cassette dosing?
[Numbers in parentheses indicate
percentage listed as top response]
(a) Maximize MS utilization and ana-
lytical (2%)
(b) Limit number of animals and an-
imal handling (29%)
(c) Maximize throughput and/or ca-
pacity for exposure screening
(69%)
(d) Reduce inter-animal variation
(0%)
QUESTION 11: What is the greatest risk or detraction
to cassette dosing?
[Numbers in parentheses indicate
percentage listed as top response]
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sults—reduced clearance due to
drug-drug interactions (67%)
(b) Chance of false negative results
(18%)
(c) Hard to correlate results with in
vitro parameters acquired for in-
dividual components (11%)
(d) Exposure throughput not rate-
limiting (expense not justified)
(14%)
QUESTION 12: Has in vitro ADME screening de-
creased your demand for cassette dos-
ing?
(a) Dramatic decline (75%) (4%)
(b) Significant decline (26 to 75%)
(16%)
(c) Noticeable decrease (10 to 25%)
(28%)
(d) No change (10%) (52%)
QUESTION 13: How would you rate your overall con-
fidence with cassette dosing?
(a) Cassette dosing gives acceptable
pharmacokinetic information and
should be the default method for
exposure screening (9%)
(b) With proper controls cassette dos-
ing can be to rank order com-
pounds (64%)
(c) Cassette dosing is justified only
when exposure information is
rate-limiting to a project (15%)
(d) Advantages do not out-weigh
risks—cassette dosing should not
be performed (12%)
Discussion
The responses to the survey captured a number of
trends, which are discussed below. Although the re-
sponses received reflect a broad coverage of the phar-
maceutical industry, no claims can be made regarding
the statistical validity of the results reported.
The response to Question 1 revealed that most of the
people surveyed do not routinely perform CD. In fact,
only 8% of the respondents use CD as their default for
exposure screening. It was further revealed from Ques-
tion 2 that those laboratories which engage in cassette
dosing employ relatively small cassettes. This trend,
which obviously reflects a desire to limit drug-drug
interactions, is consistent with recommendations made
by White and Manitpisitkul [6]. It is also consistent with
the responses received to Question 11 on the risks
associated with CD.
As predicted, rat was the most widely employed
species for CD. Interestingly, almost a quarter of the
respondents indicated large animal experience. Thisfinding is perhaps attributed to the need to conserve
large animal resources.
Questions 4 and 5 dealt with alternate routes of
administration and formulation issues, respectively.
Given the importance of CD for exposure screening, it
was interesting to find that roughly half of the time a
route other than P.O. is used for CD. Given this result,
it was somewhat surprising to learn from Question 5
that relatively few people acknowledged issues with
formulation, even though CD using I.V. dosing would
appear to be a relatively common practice. During the
discussion at the workshop it was revealed that some
practitioners filter incompletely dissolved dose solu-
tions and perform an analysis to determine the actual
I.V. dose delivered. It was not clear how widespread
this practice is.
The survey confirmed that the practice of including a
reference compound in all cassettes is a routine practice.
Nearly half of the respondents use a well-characterized
compound from the SAR that is not subject to change as
the SAR progresses. It is also noted that 27% of the
respondents do not use a reference compound in the
cassette.
Questions 7 through 9 dealt with analytical issues.
According to Question 8, just over half of the respon-
dents acknowledged that CD extends analysis time by
50%. This response was qualitatively consistent with
the results for Questions 7 and 9, which indicate that
rigorous controls over selectivity including the chro-
matographic resolution of co-administered compounds
are often not imposed; otherwise the net increase would
have likely been greater.
Question 10 leaves little doubt about the primary
motivation for CD, which is to accelerate the rate of
exposure screening. The second most cited objective is
to limit resources needed for animals and animal han-
dling. When asked about the greatest risk of CD,
two-thirds of the respondents indicated the risk associ-
ated with drug-drug interactions. Interestingly, the po-
tential for false negative results was a secondary con-
cern (18%).
Finally, Question 13 revealed that a majority of the
respondents believe that CD can be used to rank order
compounds provided proper controls are used. An
interesting finding was that 9% of the respondents use
CD as their default method for exposure screening,
while an approximately equal number (12%) state that CD
should not be applied in any circumstance. These results
speak to the polarization that continues to exist in the
pharmaceutical industry with regard to the use of CD.
Summary
Results from a survey on CD, conducted on behalf of
the ASMS Pharmaceutical Interest Group, are presented
which provide an assessment of current practices used
in the pharmaceutical industry. The purpose of the
present report is to disseminate this information, in
accordance with a key objective of the Pharmaceutical
1377J Am Soc Mass Spectrom 2004, 15, 1374–1377 CASSETTE DOSINGInterest Group to act as a conduit for benchmark
analysis on topics of pharmaceutical interest. Based the
level of interaction achieve at the 2003 workshop, it was
decided that a similar format would be used in 2004.
The topic selected for benchmark analysis is the support
of chemical synthesis by MS. In closing, gratitude is
expressed towards all who participated in the 2003
workshop.
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